FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214410092> ?p ?o ?g. }

• W3214410092 endingPage "1462" @default.
• W3214410092 startingPage "1462" @default.
• W3214410092 abstract "Abstract The Philadelphia-chromosome negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (PMF), are clonal hematopoietic stem cell disorders characterized by the proliferation of one or more myeloid lineage compartments. Activation of JAK/STAT signaling is a major driver of all Ph-negative MPNs. During disease progression, MPN patients experience increased pro-inflammatory cytokine secretion, leading to remodeling of the bone marrow microenvironment and subsequent fibrosis. The JAK inhibitor ruxolitinib is an approved targeted therapy for MPN patients and has shown promise in its ability to reduce splenomegaly and the cytokine storm observed in patients. However, JAK inhibitors alone are not sufficient to reduce bone marrow fibrosis or to eliminate the JAK2-mutated clone. Furthermore, JAK inhibitor persistence, or reactivation of JAK/STAT signaling upon chronic JAK inhibitor treatment, has been observed in both MPN mouse models and MPN patients. Therefore, there is an urgent need for new treatment options in MPN. The tyrosine kinase RON, a member of the MET kinase family, has well-characterized roles in erythroblast proliferation and pro-inflammatory cytokine production. RON can be phosphorylated by JAK2 to stimulate erythroblast proliferation. However, the role of RON in MPN pathogenesis is unknown. We found that the ALK/MET/RON/ROS1 inhibitor crizotinib inhibited colony formation by MPN patient CD34+ cells, regardless of their disease subtype, mutation status, or JAK2 inhibitor treatment history (Figure 1A). To determine whether this is due to inhibition of the JAK/STAT signaling pathway, we performed phospho-flow cytometry of STAT3 and STAT5 in myelofibrosis patient erythroblasts treated with crizotinib ex vivo as well as Western blot analysis in the JAK2-mutated cell lines SET2 and HEL. We found that crizotinib inhibits the phosphorylation of JAK2, STAT3, and STAT5 (Figure 1B). Since crizotinib has not been reported to directly inhibit JAK2, we asked whether these effects of crizotinib in MPN cells could be explained by RON inhibition. Consistent with this hypothesis, we observed that shRNA knockdown of multiple RON isoforms also decreases the phosphorylation of JAK2, STAT5, and STAT3 in HEL cells (Figure 1C-D). To determine whether crizotinib can alter the MPN disease course in vivo, we tested crizotinib by oral gavage in the MPLW515L bone marrow transplant murine model of myelofibrosis at 100mg/kg daily for 2 weeks. We showed that crizotinib decreased the disease burden of MPL-W515L mice, as evidenced by decreased spleen and liver weights (Figure 1E). To determine the effects of RON genetic deletion on MPN pathogenesis, we tested whether genetic deletion of Stk (mouse gene for RON) impairs disease progression in the JAK2V617F bone marrow transplant MPN model by transplanting Stk-/- c-Kit+ bone marrow cells transduced with the JAK2V617F-GFP retrovirus into lethally irradiated recipients. We observed a significant delay in disease onset in Stk-/- transplant recipients compared to WT controls (Figure 1F). However, we found that Stk-/- mice have normal numbers of hematopoietic stem and progenitor cells, and normal bone marrow myeloid colony forming capacity, suggesting that RON is a safe therapeutic target. To determine whether RON plays a role in the JAK inhibitor persistence phenotype, we generated persistent cells by treating SET2 cells with increasing doses of ruxolitinib over 8 weeks, and confirmed persistent proliferation and JAK/STAT activation. Interestingly, we found that RON phosphorylation is enhanced in JAK inhibitor persistent cells, and that dual inhibition of RON and JAK2 overcomes JAK inhibitor persistence in SET2 cells (Figure 1G-H), suggesting that RON may potentiate the JAK2 persistence phenotype in response to ruxolitinib. Importantly, we showed by immunoprecipitation that phospho-RON and phospho-JAK2 physically interact in JAK inhibitor persistent SET2 cells, and that this interaction is disrupted by crizotinib (Figure 1I). In summary, our data demonstrate that RON kinase is a novel mediator of JAK/STAT signaling in MPNs, and that it plays a particularly important role in JAK inhibitor persistence. Our work suggests that therapeutic strategies to inhibit RON, such as crizotinib, should be investigated in MPN patients. Figure 1 Figure 1. Disclosures Halmos: Guardant Health: Membership on an entity's Board of Directors or advisory committees; Apollomics: Membership on an entity's Board of Directors or advisory committees; TPT: Membership on an entity's Board of Directors or advisory committees; Eli-Lilly: Research Funding; Advaxis: Research Funding; Blueprint: Research Funding; Elevation: Research Funding; Mirati: Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Boehringer-Ingelheim: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra-Zeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Membership on an entity's Board of Directors or advisory committees, Research Funding. Gritsman: iOnctura: Research Funding." @default.
• W3214410092 created "2021-11-22" @default.
• W3214410092 creator A5012946103 @default.
• W3214410092 creator A5017395365 @default.
• W3214410092 creator A5040339666 @default.
• W3214410092 creator A5047223992 @default.
• W3214410092 creator A5055586203 @default.
• W3214410092 creator A5058380703 @default.
• W3214410092 creator A5058562431 @default.
• W3214410092 creator A5065834595 @default.
• W3214410092 creator A5074071919 @default.
• W3214410092 creator A5074658394 @default.
• W3214410092 creator A5075425748 @default.
• W3214410092 creator A5081356537 @default.
• W3214410092 date "2021-11-05" @default.
• W3214410092 modified "2023-09-27" @default.
• W3214410092 title "RON Kinase Is a Novel Therapeutic Target for Philadelphia-Negative Myeloproliferative Neoplasms" @default.
• W3214410092 doi "https://doi.org/10.1182/blood-2021-148192" @default.
• W3214410092 hasPublicationYear "2021" @default.
• W3214410092 type Work @default.
• W3214410092 sameAs 3214410092 @default.
• W3214410092 citedByCount "1" @default.
• W3214410092 countsByYear W32144100922022 @default.
• W3214410092 crossrefType "journal-article" @default.
• W3214410092 hasAuthorship W3214410092A5012946103 @default.
• W3214410092 hasAuthorship W3214410092A5017395365 @default.
• W3214410092 hasAuthorship W3214410092A5040339666 @default.
• W3214410092 hasAuthorship W3214410092A5047223992 @default.
• W3214410092 hasAuthorship W3214410092A5055586203 @default.
• W3214410092 hasAuthorship W3214410092A5058380703 @default.
• W3214410092 hasAuthorship W3214410092A5058562431 @default.
• W3214410092 hasAuthorship W3214410092A5065834595 @default.
• W3214410092 hasAuthorship W3214410092A5074071919 @default.
• W3214410092 hasAuthorship W3214410092A5074658394 @default.
• W3214410092 hasAuthorship W3214410092A5075425748 @default.
• W3214410092 hasAuthorship W3214410092A5081356537 @default.
• W3214410092 hasBestOaLocation W32144100921 @default.
• W3214410092 hasConcept C112392421 @default.
• W3214410092 hasConcept C126322002 @default.
• W3214410092 hasConcept C130523297 @default.
• W3214410092 hasConcept C170493617 @default.
• W3214410092 hasConcept C180361614 @default.
• W3214410092 hasConcept C203014093 @default.
• W3214410092 hasConcept C2775960820 @default.
• W3214410092 hasConcept C2776112149 @default.
• W3214410092 hasConcept C2778690821 @default.
• W3214410092 hasConcept C2778837598 @default.
• W3214410092 hasConcept C2780007613 @default.
• W3214410092 hasConcept C2780076729 @default.
• W3214410092 hasConcept C2910274570 @default.
• W3214410092 hasConcept C32465701 @default.
• W3214410092 hasConcept C502942594 @default.
• W3214410092 hasConcept C71924100 @default.
• W3214410092 hasConcept C86803240 @default.
• W3214410092 hasConceptScore W3214410092C112392421 @default.
• W3214410092 hasConceptScore W3214410092C126322002 @default.
• W3214410092 hasConceptScore W3214410092C130523297 @default.
• W3214410092 hasConceptScore W3214410092C170493617 @default.
• W3214410092 hasConceptScore W3214410092C180361614 @default.
• W3214410092 hasConceptScore W3214410092C203014093 @default.
• W3214410092 hasConceptScore W3214410092C2775960820 @default.
• W3214410092 hasConceptScore W3214410092C2776112149 @default.
• W3214410092 hasConceptScore W3214410092C2778690821 @default.
• W3214410092 hasConceptScore W3214410092C2778837598 @default.
• W3214410092 hasConceptScore W3214410092C2780007613 @default.
• W3214410092 hasConceptScore W3214410092C2780076729 @default.
• W3214410092 hasConceptScore W3214410092C2910274570 @default.
• W3214410092 hasConceptScore W3214410092C32465701 @default.
• W3214410092 hasConceptScore W3214410092C502942594 @default.
• W3214410092 hasConceptScore W3214410092C71924100 @default.
• W3214410092 hasConceptScore W3214410092C86803240 @default.
• W3214410092 hasIssue "Supplement 1" @default.
• W3214410092 hasLocation W32144100921 @default.
• W3214410092 hasOpenAccess W3214410092 @default.
• W3214410092 hasPrimaryLocation W32144100921 @default.
• W3214410092 hasRelatedWork W1543124619 @default.
• W3214410092 hasRelatedWork W1996712523 @default.
• W3214410092 hasRelatedWork W2074093544 @default.
• W3214410092 hasRelatedWork W2130365346 @default.
• W3214410092 hasRelatedWork W2143141179 @default.
• W3214410092 hasRelatedWork W2343911838 @default.
• W3214410092 hasRelatedWork W2394674019 @default.
• W3214410092 hasRelatedWork W2481496926 @default.
• W3214410092 hasRelatedWork W2545892249 @default.
• W3214410092 hasRelatedWork W2585996010 @default.
• W3214410092 hasVolume "138" @default.
• W3214410092 isParatext "false" @default.
• W3214410092 isRetracted "false" @default.
• W3214410092 magId "3214410092" @default.
• W3214410092 workType "article" @default.